NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
NEUROCRINE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $2.83B | $2.33B | $1.86B | $1.44B | $1.09B | $994.10M | $752.90M | $409.60M | $116.63M | $0 | 99.1% | +21.6% |
| Collaboration revenues | $26.60M | $24.70M | $26.50M | $47.80M | $43.40M | $51.80M | $35.20M | $41.60M | $45.00M | $15.00M | 0.9% | +7.7% |
| INGREZZA | – | $2.30B | $1.80B | $1.40B | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Neurocrine Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.